| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Net income | 274,610 | 293,989 | 242,677 | 216,149 |
| Depreciation and amortization | 36,627 | 35,772 | 34,063 | 33,706 |
| Impairment charge | 0 | 0 | 0 | 0 |
| Provision for credit losses | 1,619 | 1,470 | 2,890 | 1,787 |
| Deferred income taxes | 93,248 | 2,479 | 3,948 | -24,194 |
| Share-based compensation expense | 14,433 | 14,854 | 14,615 | 14,258 |
| Other | 1,753 | 1,035 | 456 | 184 |
| Accounts receivable | 7,697 | 29,649 | 45,240 | -27,807 |
| Inventories | -1,879 | 6,244 | -2,163 | 3,245 |
| Other assets and liabilities | 21,038 | 129,581 | 10,325 | 35,393 |
| Accounts payable | 7,136 | -3,990 | -8,123 | 5,739 |
| Deferred revenue | -230 | 5,608 | 838 | -3,643 |
| Net cash provided by operating activities | 402,340 | 185,743 | 237,962 | 262,025 |
| Purchases of property and equipment | 31,114 | 34,102 | 30,026 | 29,255 |
| Acquisition of intangible assets | 13,350 | NaN | NaN | 10,000 |
| Equity investments | 756 | NaN | NaN | 1,004 |
| Acquisition of a business | 0 | 0 | 0 | 0 |
| Proceeds from net investment hedges | 349 | 474 | 416 | 416 |
| Net cash used by investing activities | -44,871 | -33,628 | -29,610 | -39,843 |
| Borrowings under credit facility, net | -124,000 | 259,500 | 69,500 | 0 |
| Payments of senior notes | 0 | 103,386 | NaN | 0 |
| Debt issuance costs | NaN | NaN | NaN | 0 |
| Repurchases of common stock | 240,195 | 338,105 | 400,890 | 245,992 |
| Proceeds from exercises of stock options and employee stock purchase plans | 50,970 | 17,330 | 7,193 | 13,255 |
| Payments of acquisition-related contingent consideration and holdbacks | NaN | NaN | NaN | 0 |
| Shares withheld for statutory tax withholding payments on restricted stock | 85 | 970 | 6,124 | 45 |
| Net cash used by financing activities | -313,310 | -165,631 | -330,321 | -232,782 |
| Net effect of changes in exchange rates on cash | -587 | 14,140 | -2,327 | -9,770 |
| Net decrease in cash and cash equivalents | 43,572 | 624 | -124,296 | -20,370 |
| Cash and cash equivalents at beginning of period | 164,594 | 163,970 | 288,266 | 308,636 |
| Cash and cash equivalents at end of period | 208,166 | 164,594 | 163,970 | 288,266 |
IDEXX LABORATORIES INC DE (IDXX)
IDEXX LABORATORIES INC DE (IDXX)